95
Participants
Start Date
December 5, 2018
Primary Completion Date
May 7, 2021
Study Completion Date
May 7, 2022
No Study Drug was Administered in this Study
No study drug was administered in this study
Charité - Universitätsmedizin Berlin, Campus Charité Mitte; Klinik für Psychiatrie und Psychotherapi, Berlin
Georgetown University; Research Division, Psychiatry, Washington D.C.
John Hopkins University School of Medicine, Baltimore
St. Josef and St. Elisabeth gGmbH ; St. Josef Hospital Bochum; Neurologisches Forschungszentrum, Bochum
Hereditary Neurological Disease Centre (HNDC), Wichita
The University of Texas Health Science Center at Houston; McGovern Medical School, Houston
CenExel Rocky Mountain Clinical Research, LLC, Englewood
Universitätsklinikum Ulm; Klinik für Neurologie, Ulm
Columbia University, New York
The University of British Columbia; The Centre for Huntington Disease, Vancouver
Centre for Movement Disorders (Neuropharm Consulting Inc.), Markham
NIHR Welcome Trust Birmingham CRF - University Hospitals Birmingham; Department of Neuropsychiatry, Birmingham
Cardiff University School of Medicine; Institute of Psychological Medicine Clinical Neurosciences, Cardiff
National Hospital For Neurology and Neurosurgery, London
Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine, Manchester
Hoffmann-La Roche
INDUSTRY